{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T14:30:06Z","timestamp":1780756206538,"version":"3.54.1"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2026,6,1]]},"DOI":"10.2169\/internalmedicine.6118-25","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T22:08:37Z","timestamp":1760566117000},"page":"1489-1494","source":"Crossref","is-referenced-by-count":1,"title":["Effective Treatment with an Interleukin-5 Inhibitor for Recurrent Life-threatening Coronary Spastic Angina with Hypereosinophilia"],"prefix":"10.2169","volume":"65","author":[{"given":"Ryo","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Kayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Jikei University School of Medicine, Daisan Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Izumi","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"Department of General Medicine, The Jikei University School of Medicine, Daisan Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Nakamura M, Takeshita A, Nose Y. Clinical characteristics associated with myocardial infarction, arrhythmias, and sudden death in patients with vasospastic angina. Circulation 75: 1110-1116, 1987.","DOI":"10.1161\/01.CIR.75.6.1110"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yasue H, Takizawa A, Nagao M, et al. Long-term prognosis for patients with variant angina and influential factors. Circulation 78: 19, 1988.","DOI":"10.1161\/01.CIR.78.1.1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wong CW, Luis S, Zeng I, Stewart RA. Eosinophilia and coronary artery vasospasm. Heart Lung Circ 17: 488-496, 2008.","DOI":"10.1016\/j.hlc.2008.06.003"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nomura T, Keira N, Taminishi S, et al. Corticosteroid therapy was effective in controlling refractory coronary vasospasms complicated by hypereosinophilia. Intern Med 53: 735-738, 2014.","DOI":"10.2169\/internalmedicine.53.1639"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takano T, Ozaki K, Tanaka K, et al. Efficacy of corticosteroid treatment for refractory multivessel vasospastic coronary angina with hypereosinophilia. Intern Med 57: 3111-3115, 2018.","DOI":"10.2169\/internalmedicine.0886-18"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Wilson JC, Sarsour K, Gale S, Peth\u00f6-Schramm A, Jick SS, Meier CR. Incidence and risk of glucocorticoid-associated adverse effects in patients with rheumatoid arthritis. Arthritis Care Res 71: 498-511, 2019.","DOI":"10.1002\/acr.23611"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: a population-based cohort study. PLoS Med 17: e1003432, 2020.","DOI":"10.1371\/journal.pmed.1003432"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ocon AJ, Reed G, Pappas DA, et al. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis. Ann Rheum Dis 80: 1522-1529, 2021.","DOI":"10.1136\/annrheumdis-2021-220577"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. George MD, Baker JF, Winthrop K, et al. Risk for serious infection with low-dose glucocorticoids in patients with rheumatoid arthritis: a cohort study. Ann Intern Med 173: 870-878, 2020.","DOI":"10.7326\/M20-1594"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 13: 777-787, 2002.","DOI":"10.1007\/s001980200108"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ortega GH, Liu CM, Pavord DI, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198-1207, 2014.","DOI":"10.1056\/NEJMoa1403290"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Wechsler EM, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376: 1921-1932, 2017.","DOI":"10.1056\/NEJMoa1702079"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Takigawa Y, Fujiwara K, Tabuchi I, et al. Successful treatment with mepolizumab for coronary spastic angina associated with eosinophilic granulomatosis with polyangiitis. Intern Med 62: 2389-2393, 2023.","DOI":"10.2169\/internalmedicine.0930-22"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Nagase H, Miyamasu M, Yamaguchi M, et al. Expression of CXCR4 in eosinophils: functional analyses and cytokine-mediated regulation. J Immunol 164: 5935-5943, 2000.","DOI":"10.4049\/jimmunol.164.11.5935"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yamaguchi Y, Suda T, Suda J, et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 167: 43-56, 1988.","DOI":"10.1084\/jem.167.1.43"},{"key":"16","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1182\/blood.V78.10.2542.2542","volume":"78","author":"Y Yamaguchi","year":"1991","unstructured":"16. Yamaguchi Y, Suda T, Ohta S, et al. Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78: 2542-2547, 1991.","journal-title":"Blood","ISSN":"https:\/\/id.crossref.org\/issn\/0006-4971","issn-type":"print"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Egashira K, Tomoike H, Yamamoto Y, et al. Histamine-induced coronary spasm in regions of intimal thickening in miniature pigs: roles of serum cholesterol and spontaneous or induced intimal thickening. Circulation 74: 826-837, 1986.","DOI":"10.1161\/01.CIR.74.4.826"},{"key":"18","unstructured":"18. Okada H, Koganei H, Yoshioka S, et al. Multi-vasospastic angina refractory to medical therapy caused by hyperthyroid stage of chronic thyroiditis and hypereosinophilia: a case report. J Cardiol 35: 189-196, 2020."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Wong C, Luis S, Zeng I, et al. Eosinophilia and coronary artery vasospasm. Heart Lung Circ 17: 488-496, 2008.","DOI":"10.1016\/j.hlc.2008.06.003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Grayson PC, Ponte C, Suppiah R, et al.; DCVAS Study Group. 2022 American College of Rheumatology\/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 81: 309-314, 2022.","DOI":"10.1002\/art.41982"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Hokimoto S, Kaikita K, Yasuda S, et al.; Japanese Circulation Society and Japanese Association of Cardiovascular Intervention and Therapeutics and Japanese College of Cardiology Joint Working Group. JCS\/CVIT\/JCC 2023 Guideline focused update on diagnosis and treatment of vasospastic angina (Coronary spastic angina) and coronary microvascular dysfunction. Circ J 87: 879-936, 2023.","DOI":"10.1253\/circj.CJ-22-0779"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Takagi S, Goto Y, Hirose E, et al. Successful treatment of refractory vasospastic angina with corticosteroids: coronary arterial hyperactivity caused by local inflammation? Circ J 68: 17-22, 2004.","DOI":"10.1253\/circj.68.17"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Ocon AJ, Reed G, Pappas DA, Curtis JR, Kremer JM. Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid- naive patients with rheumatoid arthritis. Ann Rheum Dis 80: 1522-1529, 2021.","DOI":"10.1136\/annrheumdis-2021-220577"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Harvey ES, Langton D, Katelaris C, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J 55: 1902420, 2020.","DOI":"10.1183\/13993003.02420-2019"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med 376: 1921-1932, 2017.","DOI":"10.1056\/NEJMoa1702079"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. FitzGerald JM, Bleecker ER, Menzies-Gow A, et al. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 6: 51-64, 2018.","DOI":"10.1016\/S2213-2600(17)30344-2"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Krings JG, McGregor MC, Bacharier LB, et al. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract 7: 1379-1392, 2019.","DOI":"10.1016\/j.jaip.2019.03.008"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Nakazawa N, Katsuki T, Fujisawa T, et al. Refractory vasospastic angina complicated by bronchial asthma with eosinophilia. Intern Med 64: 1359-1364, 2025.","DOI":"10.2169\/internalmedicine.3736-24"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6118-25\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:29:41Z","timestamp":1780716581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/65\/11\/65_6118-25\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.6118-25","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"6118-25"}}